Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
Kessler
J M
JM
Duke University Medical Center, Durham, NC 27710, USA.
D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D003657:Decision Making; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D005569:Formularies as Topic; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000191:economics; D000960:Hypolipidemic Agents / Q000191:economics* / Q000627:therapeutic use; D010606:Pharmacy and Therapeutics Committee / Q000191:economics*; D014481:United States
D000960:Hypolipidemic Agents